Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- TBI
- Reported indication
- Historical sedative/hypnotic (bromisoval); no modern approved indication - sale banned in most countries
- First approval
- Not recorded
- Development stage
- Withdrawn legacy sedative; not developed for any acute injury
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Bromovalerylurea; Bromisoval; Bromisovalum; Bromural; 2-bromo-3-methylbutyrylurea; Bromvalerylurea; Calmotin; Brovarin; Dormigene
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatTBIPenetrating / ballisticWistarMale
Model: Stab wound traumatic brain injury
Bromovalerylurea inhibited CCL2 expression, monocyte and macrophage accumulation, 8-hydroxy-2'-deoxyguanosine and mitochondrial reactive oxygen species generation and pro-inflammatory cytokine expression, and markedly improved outcome, without inhibiting microglial activation or TGF-beta1 and IGF-1…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.
